Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 10.7% - Still a Buy?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) rose 10.7% during mid-day trading on Wednesday . The stock traded as high as $12.05 and last traded at $11.78. Approximately 29,323,578 shares traded hands during mid-day trading, an increase of 21% from the average daily volume of 24,262,922 shares. The stock had previously closed at $10.64.

Analyst Ratings Changes

RXRX has been the subject of several analyst reports. KeyCorp reduced their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th.

Recursion Pharmaceuticals Stock Down 10.3 %

The stock has a market cap of $3.63 billion, a P/E ratio of -6.07 and a beta of 0.86. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm's fifty day moving average is $7.56 and its 200 day moving average is $7.02.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its holdings in shares of Recursion Pharmaceuticals by 17.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company's stock worth $12,789,000 after purchasing an additional 288,926 shares during the period. Accel Wealth Management bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth about $310,000. FMR LLC increased its holdings in shares of Recursion Pharmaceuticals by 2.1% during the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company's stock worth $55,116,000 after purchasing an additional 170,810 shares during the period. Avanza Fonder AB bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth about $580,000. Finally, State Street Corp increased its holdings in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after purchasing an additional 4,120,685 shares during the period. Institutional investors own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.